HPV is extraordinarily common. About 85% of people will get at least one HPV infection in their lifetime, and at any given time, roughly 40% of women in the United States are carrying some form of the virus. Globally, the picture varies by region, but the bottom line is the same: most sexually active women will encounter HPV at some point.
Current Prevalence in the U.S.
National health surveys from 2013 to 2014 found that 39.9% of American women aged 18 to 59 tested positive for at least one of 37 HPV types. That translates to roughly 4 in 10 women carrying the virus at the time of testing. Men had a slightly higher rate at 45.2%, putting the overall adult prevalence at 42.5%.
Not all of those infections are the dangerous kind. About 20.4% of women in that same survey carried high-risk HPV types, the strains linked to cancer. The remaining infections involved low-risk types that can cause genital warts or produce no symptoms at all.
Global Numbers by Region
Worldwide, roughly 11 to 12% of women with no cervical abnormalities test positive for HPV at any given time. That lower global figure compared to the U.S. reflects differences in testing methods and population sampling, but it still represents hundreds of millions of women. The highest regional prevalence is in sub-Saharan Africa at 24%, followed by Eastern Europe at 21% and Latin America at 16%. Access to vaccination and screening programs largely explains the gap between regions.
High-Risk vs. Low-Risk Strains
There are over 200 known HPV types, but only a handful cause serious health problems. The most important distinction is between high-risk and low-risk strains.
HPV type 16 alone causes about 50% of cervical cancers worldwide. Types 16 and 18 together account for roughly 66%. High-risk strains are detected in 99% of cervical precancers, making persistent infection with these types the primary driver of the disease. More than 9 out of every 10 cervical cancer cases in the U.S. are caused by HPV.
Low-risk types, particularly 6 and 11, are responsible for more than 90% of genital warts cases. These strains are a nuisance but don’t lead to cancer.
Most Infections Clear on Their Own
Getting an HPV infection doesn’t mean you’ll develop cancer or even warts. The immune system clears most infections without treatment. Research tracking infection timelines found that about 75% of HPV infections clear within 12 months of first being detected, with a median clearance time of just under 6 months. By 18 months, roughly 90% of infections are gone.
The infections that matter most are the ones that persist. When a high-risk HPV type sticks around for years, it can cause cell changes that eventually become precancerous. This is why routine cervical screening exists: it catches those slow-developing changes long before they become cancer. The window between a persistent infection and actual cancer is typically a decade or more, giving screening plenty of time to intervene.
How Vaccination Has Changed the Numbers
The HPV vaccine was introduced in 2006, and its impact on infection rates among young women has been dramatic. CDC surveillance data comparing the pre-vaccine era (2003 to 2006) to the period from 2015 to 2018 found an 88% drop in vaccine-type HPV infections among females aged 14 to 19 and an 81% drop among those aged 20 to 24.
The numbers are even more striking when broken down by vaccination status. Among sexually experienced females aged 14 to 19, the prevalence of vaccine-targeted HPV types dropped from 19.3% before the vaccine to just 0.6% among those who were vaccinated. That’s a 97% reduction. Even unvaccinated women in the same age group saw an 87% decrease, falling to 2.4%, a sign of herd protection as fewer people carry and transmit the virus.
For women aged 20 to 24, vaccinated individuals saw an 86% reduction (down to 2.5%), while unvaccinated women experienced a 65% decrease (down to 6.3%). These declines are expected to continue as vaccinated generations age and make up a larger share of the adult population.
What the Lifetime Risk Really Means
The 85% lifetime infection estimate can sound alarming, but context matters. Most of those infections are transient, cause no symptoms, and resolve without the person ever knowing they had the virus. There’s no blood test for HPV that’s routinely used, and many infections are only detected through cervical screening or research studies. A positive HPV result on a screening test is not a diagnosis of disease. It’s a signal that your body is dealing with a very common virus, and in most cases, it will handle it successfully.
The small percentage of infections that persist and involve high-risk types are the ones that require monitoring. This is why cervical screening guidelines are built around HPV testing at regular intervals rather than one-time checks. If a high-risk type is still present on a follow-up test, your provider can look more closely at the cervical cells and intervene early if anything is changing.